A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma.

Shaw, D M

A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. [electronic resource] - British journal of cancer Feb 2007 - 567-74 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't

0007-0920

10.1038/sj.bjc.6603567 doi


Adult
Aged
Antigens, Neoplasm--immunology
Carcinoma, Renal Cell--diagnosis
Disease Progression
Dose-Response Relationship, Drug
Drug-Related Side Effects and Adverse Reactions
Enterotoxins--administration & dosage
Female
Follow-Up Studies
Humans
Injections, Intravenous
Interleukin-2--biosynthesis
Kidney Neoplasms--diagnosis
Male
Membrane Glycoproteins--administration & dosage
Middle Aged
Predictive Value of Tests
Prognosis
Recombinant Fusion Proteins--administration & dosage
Survival Rate
Treatment Outcome